PPAR Research

PPAR Research / 2006 / Article

Review Article | Open Access

Volume 2006 |Article ID 073986 | https://doi.org/10.1155/PPAR/2006/73986

Pascal Froment, Philippe Touraine, "Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS)", PPAR Research, vol. 2006, Article ID 073986, 8 pages, 2006. https://doi.org/10.1155/PPAR/2006/73986

Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS)

Received15 Jul 2006
Revised13 Oct 2006
Accepted17 Oct 2006
Published06 Nov 2006

Abstract

Polycystic ovary syndrome (PCOS) is the most frequent cause of female infertility. The treatment of PCOS patients with insulin sensitizers, such as metformin or thiazolidinediones, increases the ovulation rate and the number of successful pregnancies. The positive action of the insulin-sensitizing treatments could be explained by a decrease in the peripheral insulin resistance but also by a direct action at the ovarian level. We report in this review different hypotheses of thiazolidinediones actions to improve PCOS (steroid secretion by ovarian cells ; insulin sensitivity in muscle and adipocyte and fat redistribution).

References

  1. A Dunaif, “Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis,” Endocrine Reviews, vol. 18, no. 6, pp. 774–800, 1997. View at: Publisher Site | Google Scholar
  2. C Deneux and F Kuttenn, “Hyperandrogenism and fertility,” Annales d'Endocrinologie, vol. 59, no. 4, pp. 311–318, 1998. View at: Google Scholar
  3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome,” Fertility and Sterility, vol. 81, no. 1, pp. 19–25, 2004. View at: Publisher Site | Google Scholar
  4. A Dunaif, “Insulin action in the polycystic ovary syndrome,” Endocrinology and Metabolism Clinics of North America, vol. 28, no. 2, pp. 341–359, 1999. View at: Publisher Site | Google Scholar
  5. S SC Yen, “The polycystic ovary syndrome,” Clinical Endocrinology, vol. 12, no. 2, pp. 177–207, 1980. View at: Google Scholar
  6. J C Marshall and C A Eagleson, “Neuroendocrine aspects of polycystic ovary syndrome,” Endocrinology and Metabolism Clinics of North America, vol. 28, no. 2, pp. 295–324, 1999. View at: Publisher Site | Google Scholar
  7. K A Risma, C M Clay, T M Nett, T Wagner, J Yun, and J H Nilson, “Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 5, pp. 1322–1326, 1995. View at: Publisher Site | Google Scholar
  8. L Poretsky, “Polycystic ovary syndrome—increased or preserved ovarian sensitivity to insulin?,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 8, pp. 2859–2860, 2006. View at: Publisher Site | Google Scholar
  9. J R Wood, V L Nelson, C Ho et al., “The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis,” Journal of Biological Chemistry, vol. 278, no. 29, pp. 26380–26390, 2003. View at: Publisher Site | Google Scholar
  10. R B Barnes, “Pathophysiology of ovarian steroid secretion in polycystic ovary syndrome,” Seminars in Reproductive Endocrinology, vol. 15, no. 2, pp. 159–168, 1997. View at: Google Scholar
  11. S Franks, C Gilling-Smith, H Watson, and D Willis, “Insulin action in the normal and polycystic ovary,” Endocrinology and Metabolism Clinics of North America, vol. 28, no. 2, pp. 361–378, 1999. View at: Publisher Site | Google Scholar
  12. C Bergh, B Carlsson, J-H Olsson, U Selleskog, and T Hillensjo, “Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin,” Fertility and Sterility, vol. 59, no. 2, pp. 323–331, 1993. View at: Google Scholar
  13. S K Blank, C R McCartney, and J C Marshall, “The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome,” Human Reproduction Update, vol. 12, no. 4, pp. 351–361, 2006. View at: Publisher Site | Google Scholar
  14. V De Leo, A La Marca, and F Petraglia, “Insulin-lowering agents in the management of polycystic ovary syndrome,” Endocrine Reviews, vol. 24, no. 5, pp. 633–667, 2003. View at: Publisher Site | Google Scholar
  15. M J Iuorno and J E Nestler, “Insulin-lowering drugs in polycystic ovary syndrome,” Obstetrics and Gynecology Clinics of North America, vol. 28, no. 1, pp. 153–164, 2001. View at: Publisher Site | Google Scholar
  16. J E Nestler, D J Jakubowicz, P Reamer, R D Gunn, and G Allan, “Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome,” New England Journal of Medicine, vol. 340, no. 17, pp. 1314–1320, 1999. View at: Publisher Site | Google Scholar
  17. E Seli and A J Duleba, “Treatment of PCOS with metformin and other insulin-sensitizing agents,” Current Diabetes Reports, vol. 4, no. 1, pp. 69–75, 2004. View at: Google Scholar
  18. J M Lehmann, L B Moore, T A Smith-Oliver, W O Wilkison, T M Willson, and S A Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at: Publisher Site | Google Scholar
  19. B Desvergne and W Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at: Publisher Site | Google Scholar
  20. H N Sørensen, E Treuter, and J A Gustafsson, “Regulation of peroxisome proliferator-activated receptors,” Vitamins and Hormones, vol. 54, pp. 121–166, 1998. View at: Google Scholar
  21. F Picard and J Auwerx, “PPARγ and glucose homeostasis,” Annual Review of Nutrition, vol. 22, pp. 167–197, 2002. View at: Publisher Site | Google Scholar
  22. J Girard, “Mechanisms of action of thiazolidinediones,” Diabetes and Metabolism, vol. 27, no. 2 pt 2, pp. 271–278, 2001. View at: Google Scholar
  23. M Gurnell, D B Savage, V KK Chatterjee, and S O'Rahilly, “The metabolic syndrome: peroxisome proliferator-activated receptor γ and its therapeutic modulation,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2412–2421, 2003. View at: Publisher Site | Google Scholar
  24. B Staels and J-C Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” Diabetes, vol. 54, no. 8, pp. 2460–2470, 2005. View at: Google Scholar
  25. C M Komar, “Peroxisome proliferator-activated receptors (PPARs) and ovarian function—implications for regulating steroidogenesis, differentiation, and tissue remodeling,” Reproductive Biology and Endocrinology, vol. 3, p. 41, 2005. View at: Publisher Site | Google Scholar
  26. P Froment, F Gizard, D Defever, B Staels, J Dupont, and P Monget, “Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition,” Journal of Endocrinology, vol. 189, no. 2, pp. 199–209, 2006. View at: Publisher Site | Google Scholar
  27. C M Komar, O Braissant, W Wahli, and T E Jr Curry, “Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period,” Endocrinology, vol. 142, no. 11, pp. 4831–4838, 2001. View at: Publisher Site | Google Scholar
  28. C M Komar and T E Jr Curry, “Inverse relationship between the expression of messenger ribonucleic acid for peroxisome proliferator-activated receptor γ and P450 side chain cleavage in the rat ovary,” Biology of Reproduction, vol. 69, no. 2, pp. 549–555, 2003. View at: Publisher Site | Google Scholar
  29. A Abe, Y Kiriyama, M Hirano et al., “Troglitazone suppresses cell growth of KU812 cells independently of PPARγ,” European Journal of Pharmacology, vol. 436, no. 1-2, pp. 7–13, 2002. View at: Publisher Site | Google Scholar
  30. N K LeBrasseur, M Kelly, T-S Tsao et al., “Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues,” American Journal of Physiology - Endocrinology and Metabolism, vol. 291, no. 1, pp. E175–E181, 2006. View at: Publisher Site | Google Scholar
  31. M A Khan, J V St. Peter, and J L Xue, “A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone,” Diabetes Care, vol. 25, no. 4, pp. 708–711, 2002. View at: Google Scholar
  32. D L Stout and S E Fugate, “Thiazolidinediones for treatment of polycystic ovary syndrome,” Pharmacotherapy, vol. 25, no. 2, pp. 244–252, 2005. View at: Publisher Site | Google Scholar
  33. R Azziz, D Ehrmann, R S Legro et al., “Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 4, pp. 1626–1632, 2001. View at: Publisher Site | Google Scholar
  34. I Hasegawa, H Murakawa, M Suzuki, Y Yamamoto, T Kurabayashi, and K Tanaka, “Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome,” Fertility and Sterility, vol. 71, no. 2, pp. 323–327, 1999. View at: Publisher Site | Google Scholar
  35. D A Ehrmann, D J Schneider, B E Sobel et al., “Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 7, pp. 2108–2116, 1997. View at: Publisher Site | Google Scholar
  36. A Dunaif, D Scott, D Finegood, B Quintana, and R Whitcomb, “The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 9, pp. 3299–3306, 1996. View at: Publisher Site | Google Scholar
  37. D Glintborg, A P Hermann, M Andersen et al., “Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 86, no. 2, pp. 385–397, 2006. View at: Publisher Site | Google Scholar
  38. H M Garmes, M A Tambascia, and D E Zantut-Wittmann, “Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome,” Gynecological Endocrinology, vol. 21, no. 6, pp. 317–323, 2005. View at: Publisher Site | Google Scholar
  39. N Brettenthaler, C De Geyter, P R Huber, and U Keller, “Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 8, pp. 3835–3840, 2004. View at: Publisher Site | Google Scholar
  40. D Romualdi, M Guido, M Ciampelli et al., “Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome,” Human Reproduction, vol. 18, no. 6, pp. 1210–1218, 2003. View at: Publisher Site | Google Scholar
  41. N A Cataldo, F Abbasi, T L McLaughlin, C Lamendola, and G M Reaven, “Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone,” Fertility and Sterility, vol. 76, no. 5, pp. 1057–1059, 2001. View at: Publisher Site | Google Scholar
  42. N A Cataldo, F Abbasi, T L McLaughlin et al., “Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome,” Human Reproduction, vol. 21, no. 1, pp. 109–120, 2006. View at: Publisher Site | Google Scholar
  43. V Sepilian and M Nagamani, “Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 1, pp. 60–65, 2005. View at: Publisher Site | Google Scholar
  44. S H Belli, M N Graffigna, A Oneto, P Otero, L Schurman, and O A Levalle, “Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 81, no. 3, pp. 624–629, 2004. View at: Publisher Site | Google Scholar
  45. M FM Mitwally, N K Kuscu, and T M Yalcinkaya, “High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome,” Human Reproduction, vol. 14, no. 11, pp. 2700–2703, 1999. View at: Publisher Site | Google Scholar
  46. G Ghazeeri, W H Kutteh, M Bryer-Ash, D Haas, and R W Ke, “Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 79, no. 3, pp. 562–566, 2003. View at: Publisher Site | Google Scholar
  47. C Ortega-González, S Luna, L Hernández et al., “Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 3, pp. 1360–1365, 2005. View at: Publisher Site | Google Scholar
  48. Y Barak, M C Nelson, E S Ong et al., “PPARγ is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999. View at: Publisher Site | Google Scholar
  49. J Sevillano, I C López-Pérez, E Herrera, M Del Pilar Ramos, and C Bocos, “Englitazone administration to late pregnant rats produces delayed body growth and insulin resistance in their fetuses and neonates,” Biochemical Journal, vol. 389, no. 3, pp. 913–918, 2005. View at: Publisher Site | Google Scholar
  50. F Yaris, E Yaris, M Kadioglu, C Ulku, M Kesim, and N I Kalyoncu, “Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman,” Reproductive Toxicology, vol. 18, no. 4, pp. 619–621, 2004. View at: Publisher Site | Google Scholar
  51. N I Kalyoncu, F Yaris, C Ulku et al., “A case of rosiglitazone exposure in the second trimester of pregnancy,” Reproductive Toxicology, vol. 19, no. 4, pp. 563–564, 2005. View at: Publisher Site | Google Scholar
  52. C J Glueck, H Phillips, D Cameron, L Sieve-Smith, and P Wang, “Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study,” Fertility and Sterility, vol. 75, no. 1, pp. 46–52, 2001. View at: Publisher Site | Google Scholar
  53. A H Balen, S-L Tan, J MacDougall, and H S Jacobs, “Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin,” Human Reproduction, vol. 8, no. 6, pp. 959–964, 1993. View at: Google Scholar
  54. L Harborne, R Fleming, H Lyall, J Norman, and N Sattar, “Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome,” Lancet, vol. 361, no. 9372, pp. 1894–1901, 2003. View at: Publisher Site | Google Scholar
  55. R V Mehta, K S Patel, M S Coffler et al., “Luteinizing hormone secretion is not influenced by insulin infusion in women with polycystic ovary syndrome despite improved insulin sensitivity during pioglitazone treatment,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 4, pp. 2136–2141, 2005. View at: Publisher Site | Google Scholar
  56. J A Downing and R J Scaramuzzi, “Nutrient effects on ovulation rate, ovarian function and the secretion of gonadotrophic and metabolic hormones in sheep,” Journal of Reproduction and Fertility. Supplement, vol. 43, pp. 209–227, 1991. View at: Google Scholar
  57. D I Lebovic, M Kir, and C L Casey, “Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis,” Fertility and Sterility, vol. 82, no. suppl 3, pp. 1008–1013, 2004. View at: Publisher Site | Google Scholar
  58. Y Cui, K Miyoshi, E Claudio et al., “Loss of the peroxisome proliferation-activated receptor gamma (PPARγ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility,” Journal of Biological Chemistry, vol. 277, no. 20, pp. 17830–17835, 2002. View at: Publisher Site | Google Scholar
  59. D Duffy, G Montgomery, S Treloar et al., “IBD sharing around the PPARG locus is not increased in dizygotic twins or their mothers,” Nature Genetics, vol. 28, no. 4, p. 315, 2001. View at: Publisher Site | Google Scholar
  60. D Seto-Young, M Paliou, J Schlosser et al., “Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 11, pp. 6099–6105, 2005. View at: Publisher Site | Google Scholar
  61. Y-M Mu, T Yanase, Y Nishi et al., “Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells,” Biochemical and Biophysical Research Communications, vol. 271, no. 3, pp. 710–713, 2000. View at: Publisher Site | Google Scholar
  62. D S Willis, J White, S Brosens, and S Franks, “Effect of 15-deoxy-(12,14)-prostaglandin J2(PGJ2) a peroxisome proliferator activating receptor (PPAR) ligand on human ovarian steroidogenesis,” Endocrinology, no. suppl 1, p. 491, 1999, (abstract P3-247). View at: Google Scholar
  63. J D Veldhuis, G Zhang, and J C Garmey, “Troglitazone, an insulin-sensitizing thiazolidinedione, represses combined stimulation by LH and insulin of de novo androgen biosynthesis by thecal cells in vitro,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 3, pp. 1129–1133, 2002. View at: Publisher Site | Google Scholar
  64. S Gasic, M Nagamani, A Green, and R J Urban, “Troglitazone is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase enzyme in the ovary,” American Journal of Obstetrics and Gynecology, vol. 184, no. 4, pp. 575–579, 2001. View at: Publisher Site | Google Scholar
  65. M S Coffler, K Patel, M H Dahan, R Y Yoo, P J Malcom, and R J Chang, “Enhanced granulosa cell responsiveness to follicle-stimulating hormone during insulin infusion in women with polycystic ovary syndrome treated with pioglitazone,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 12, pp. 5624–5631, 2003. View at: Publisher Site | Google Scholar
  66. D Avtanski, J Kaplun, M Strizhevsky et al., “Interactions among PPAR-, insulin signaling pathways and aromatase in human ovarian cells,” in Proceedings of the 88th Annual Meeting of the Endocrine Society (ENDO '06), Boston, Mass, June 2006, (abstract P1-397). View at: Google Scholar
  67. A Dunaif and A Thomas, “Current concepts in the polycystic ovary syndrome,” Annual Review of Medicine, vol. 52, pp. 401–419, 2001. View at: Publisher Site | Google Scholar
  68. T Yamauchi, J Kamon, H Waki et al., “The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance,” Journal of Biological Chemistry, vol. 276, no. 44, pp. 41245–41254, 2001. View at: Publisher Site | Google Scholar
  69. J Holte, T Bergh, C Berne, and H Lithell, “Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables,” Clinical Endocrinology, vol. 41, no. 4, pp. 463–471, 1994. View at: Google Scholar
  70. A A Parulkar, M L Pendergrass, R Granda-Ayala, T R Lee, and V A Fonseca, “Nonhypoglycemic effects of thiazolidinediones,” Annals of Internal Medicine, vol. 134, no. 1, pp. 61–71, 2001. View at: Google Scholar
  71. G W Bates and N S Whitworth, “Effect of body weight reduction on plasma androgens in obese, infertile women,” Fertility and Sterility, vol. 38, no. 4, pp. 406–409, 1982. View at: Google Scholar
  72. M-M Huber-Buchholz, D GP Carey, and R J Norman, “Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 4, pp. 1470–1474, 1999. View at: Publisher Site | Google Scholar
  73. T M Larsen, S Toubro, and A Astrup, “PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy?,” International Journal of Obesity, vol. 27, no. 2, pp. 147–161, 2003. View at: Publisher Site | Google Scholar
  74. P Arner, “The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones,” Trends in Endocrinology and Metabolism, vol. 14, no. 3, pp. 137–145, 2003. View at: Publisher Site | Google Scholar
  75. P Björntorp, “The regulation of adipose tissue distribution in humans,” International Journal of Obesity, vol. 20, no. 4, pp. 291–302, 1996. View at: Google Scholar
  76. J Lord, R Thomas, B Fox, U Acharya, and T Wilkin, “The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome,” BJOG: An International Journal of Obstetrics & Gynaecology, vol. 113, no. 10, pp. 1203–1209, 2006. View at: Publisher Site | Google Scholar
  77. E Budak, M Fernández Sánchez, J Bellver, A Cerveró, C Simón, and A Pellicer, “Interactions of the hormones leptin, ghrelin, adiponectin, resistin, and PYY3-36 with the reproductive system,” Fertility and Sterility, vol. 85, no. 6, pp. 1563–1581, 2006. View at: Publisher Site | Google Scholar
  78. F Gonzalez, K Thusu, E Abdel-Rahman, A Prabhala, M Tomani, and P Dandona, “Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome,” Metabolism, vol. 48, no. 4, pp. 437–441, 1999. View at: Publisher Site | Google Scholar
  79. H F Escobar-Morreale, G Villuendas, J I Botella-Carretero et al., “Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study,” Human Reproduction, vol. 21, no. 9, pp. 2257–2265, 2006. View at: Publisher Site | Google Scholar
  80. A Okuno, H Tamemoto, K Tobe et al., “Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats,” Journal of Clinical Investigation, vol. 101, no. 6, pp. 1354–1361, 1998. View at: Google Scholar
  81. C R Kahn, L Chen, and S E Cohen, “Unraveling the mechanism of action of thiazolidinediones,” Journal of Clinical Investigation, vol. 106, no. 11, pp. 1305–1307, 2000. View at: Google Scholar
  82. D Duran-Sandoval, A-C Thomas, B Bailleul, J-C Fruchart, and B Staels, “Pharmacology of PPARα, PPARγ and dual PPARα/γ agonists in clinical development,” Medecine/Sciences, vol. 19, no. 8-9, pp. 819–825, 2003. View at: Google Scholar
  83. A Bodles, A Banga, N Rasouli, F Ono, P A Kern, and R J Owens, “Pioglitazone increases secretion of high-molecular-weight adiponectin from adipocytes,” American Journal of Physiology - Endocrinology and Metabolism, vol. 291, no. 5, pp. E1100–E1105, 2006. View at: Publisher Site | Google Scholar
  84. V Sepilian and M Nagamani, “Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance,” Journal of the Society for Gynecologic Investigation, vol. 12, no. 2, pp. 129–134, 2005. View at: Publisher Site | Google Scholar
  85. F Jr Orio, S Palomba, T Cascella et al., “Adiponectin levels in women with polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 6, pp. 2619–2623, 2003. View at: Publisher Site | Google Scholar
  86. I Munir, H-W Yen, T Baruth et al., “Resistin stimulation of 17α-hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 8, pp. 4852–4857, 2005. View at: Publisher Site | Google Scholar
  87. J M Lord, I HK Flight, and R J Norman, “Metformin in polycystic ovary syndrome: systematic review and meta-analysis,” British Medical Journal, vol. 327, no. 7421, pp. 951–953, 2003. View at: Publisher Site | Google Scholar
  88. R J Norman, “Editorial: metformin—comparison with other therapies in ovulation induction in polycystic ovary syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 10, pp. 4797–4800, 2004. View at: Publisher Site | Google Scholar
  89. N Musi, M F Hirshman, J Nygren et al., “Metformin increases AMP-activated protein-kinase activity in skeletal muscle of subjects with type 2 diabetes,” Diabetes, vol. 51, no. 7, pp. 2074–2081, 2002. View at: Google Scholar
  90. L Tosca, P Solnais, P Ferré, F Foufelle, and J Dupont, “Metformin-induced stimulation of adenosine 5 monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells,” Biology of Reproduction, vol. 75, no. 3, pp. 342–351, 2006. View at: Publisher Site | Google Scholar
  91. R Mansfield, R Galea, M Brincat, D Hole, and H Mason, “Metformin has direct effects on human ovarian steroidogenesis,” Fertility and Sterility, vol. 79, no. 4, pp. 956–962, 2003. View at: Publisher Site | Google Scholar
  92. A La Marca, T O Egbe, G Morgante, T Paglia, A Ciani, and V De Leo, “Metformin treatment reduces ovarian cytochrome P-450c17α response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome,” Human Reproduction, vol. 15, no. 1, pp. 21–23, 2000. View at: Publisher Site | Google Scholar
  93. M R Owen, E Doran, and A P Halestrap, “Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain,” Biochemical Journal, vol. 348, no. 3, pp. 607–614, 2000. View at: Publisher Site | Google Scholar
  94. L A Stadtmauer, S K Toma, R M Riehl, and L M Talbert, “Impact of metformin therapy on ovarian stimulation and outcome in ‘coasted’ patients with polycystic ovary syndrome undergoing in-vitro fertilization,” Reproductive Biomedicine Online, vol. 5, no. 2, pp. 112–116, 2002. View at: Google Scholar
  95. J-P Baillargeon, D J Jakubowicz, M J Iuorno, S Jakubowicz, and J E Nestler, “Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity,” Fertility and Sterility, vol. 82, no. 4, pp. 893–902, 2004. View at: Publisher Site | Google Scholar
  96. A A Rouzi and M SM Ardawi, “A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome,” Fertility and Sterility, vol. 85, no. 2, pp. 428–435, 2006. View at: Publisher Site | Google Scholar
  97. M Yilmaz, A Karakoç, F B Törüner et al., “The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome,” Gynecological Endocrinology, vol. 21, no. 3, pp. 154–160, 2005. View at: Google Scholar
  98. C J Glueck, A Moreira, N Goldenberg, L Sieve, and P Wang, “Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin,” Human Reproduction, vol. 18, no. 8, pp. 1618–1625, 2003. View at: Publisher Site | Google Scholar
  99. C Xu, L-L Wang, H-Y Liu et al., “A novel dual peroxisome proliferator-activated receptors α and γ agonist with beneficial effects on insulin resistance and lipid metabolism,” Biotechnology Letters, vol. 28, no. 12, pp. 863–868, 2006. View at: Publisher Site | Google Scholar
  100. C Fievet, J C Fruchart, and B Staels, “PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome,” Current Opinion in Pharmacology, vol. 6, no. 6, pp. 606–614, 2006. View at: Google Scholar

Copyright © 2006 Pascal Froment and Philippe Touraine. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

260 Views | 848 Downloads | 34 Citations
 PDF Download Citation Citation
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.